AYOXXA Biosystems, a specialist in the development of multiplex protein analysis assays for drug discovery and translational research, has closed a funding round led by Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network.
Besides Prosnav, a group of existing shareholders participated in the financing.
The funds will be used to drive the global commercialisation of AYOXXA’s LUNARIS platform. The platform is designed to generate high-quality proteomics data using smallest-volume samples. It enables fully scalable quantitative validation of disease-relevant biomarkers and allows for translational research from laboratory to clinic, from mouse model to human, from data to treatment or vaccine.
Continuing investors led by Wellington Partners and NRW.Bank include b-to-v Partners; Rainer Christine Asset Management GmbH.; Equivation-Beteiligungsgesellschaft mbH; Roland Oetker Family Office; Riesner Verwaltungs, the two Co-Founders of AYOXXA and several other private investors.
